Phathom Pharmaceuticals (PHAT) Free Cash Flow (2022 - 2026)
Phathom Pharmaceuticals (PHAT) has disclosed Free Cash Flow for 5 consecutive years, with -$15.6 million as the latest value for Q1 2026.
- For Q1 2026, Free Cash Flow rose 81.58% year-over-year to -$15.6 million; the TTM value through Mar 2026 reached -$97.7 million, up 65.45%, while the annual FY2025 figure was -$167.0 million, 37.43% up from the prior year.
- Free Cash Flow hit -$15.6 million in Q1 2026 for Phathom Pharmaceuticals, down from -$5.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$5.2 million in Q4 2025 and bottomed at -$84.9 million in Q1 2025.
- Average Free Cash Flow over 5 years is -$43.2 million, with a median of -$40.6 million recorded in 2022.
- Year-over-year, Free Cash Flow plummeted 218.49% in 2024 and then skyrocketed 91.84% in 2025.
- Phathom Pharmaceuticals' Free Cash Flow stood at -$40.6 million in 2022, then decreased by 5.19% to -$42.7 million in 2023, then plummeted by 48.77% to -$63.5 million in 2024, then surged by 91.84% to -$5.2 million in 2025, then crashed by 202.12% to -$15.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods came in at -$15.6 million, -$5.2 million, and -$14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.